iNtRON Biotechnology, Inc.
KOSDAQTotal Valuation
iNtRON Biotechnology, Inc. carries a market capitalization of 71.98B, placing it among publicly traded companies globally. Its enterprise value stands at 100.20B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 71.98B |
| Enterprise Value | 100.20B |
Share Statistics
iNtRON Biotechnology, Inc. currently has 30.89M shares outstanding.
| Shares Outstanding | 30.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 20.47, and the price-to-book ratio stands at 5.13.
| PE Ratio | N/A |
| PS Ratio | 20.47 |
| PB Ratio | 5.13 |
| P/TBV Ratio | 2.08 |
| P/FCF Ratio | -52.33 |
| P/OCF Ratio | -28.09 |
Enterprise Valuation
| EV / Sales | 15.57 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 71.77 |
Financial Position
iNtRON Biotechnology, Inc. maintains a current ratio of 9.81, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.89, indicating elevated leverage, while an interest coverage ratio of -70.70 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.81 |
| Quick Ratio | 8.80 |
| Debt / Equity | 7.89 |
| Debt / EBITDA | -0.62 |
| Interest Coverage | -70.70 |
Financial Efficiency
| Return on Equity (ROE) | -22.88 |
| Return on Assets (ROA) | -11.99 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.34 |
Taxes
| Income Tax | -101.63M |
| Effective Tax Rate | N/A |
Stock Price Statistics
iNtRON Biotechnology, Inc.'s stock has declined approximately -41.16162% over the past 52 weeks. The 50-day moving average sits at 2,922.80, while the 200-day moving average is 3,565.30.
| Beta (5Y) | N/A |
| 52-Week Price Change | -41.16162% |
| 50-Day Moving Average | 2,922.80 |
| 200-Day Moving Average | 3,565.30 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, iNtRON Biotechnology, Inc. generated 6.44B in revenue and converted that into -9.19B in net income, yielding earnings per share of -292.21. EBITDA reached -8.23B, while operating income came in at -8.23B.
| Revenue | 6.44B |
| Gross Profit | 3.34B |
| Operating Income | -8.23B |
| Pretax Income | -9.29B |
| Net Income | -9.19B |
| EBITDA | -8.23B |
| EBIT | -8.23B |
| Earnings Per Share (EPS) | -292.21 |
Balance Sheet
iNtRON Biotechnology, Inc. holds 36.62B in cash and equivalents against 5.08B in total debt, resulting in a net debt position of -20.26B. Total book value stands at 25.69B, with working capital of 36.65B providing operational flexibility.
| Cash & Cash Equivalents | 36.62B |
| Total Debt | 5.08B |
| Net Debt | -20.26B |
| Equity (Book Value) | 25.69B |
| Book Value Per Share | 795.66 |
| Working Capital | 36.65B |
Cash Flow
iNtRON Biotechnology, Inc. produced -4.69B in operating cash flow over the past twelve months. After subtracting -2.24B in capital expenditures, free cash flow totaled -6.93B - equivalent to -214.56 per share.
| Operating Cash Flow | -4.69B |
| Capital Expenditures | -2.24B |
| Free Cash Flow | -6.93B |
| FCF Per Share | -214.56 |
Margins
iNtRON Biotechnology, Inc. operates with a gross margin of 51.89, reflecting its pricing power and cost economics. The operating margin of -127.86 and net profit margin of -142.74 provide insight into operational efficiency.
| Gross Margin | 51.89 |
| Operating Margin | -127.86 |
| Pretax Margin | -144.32 |
| Profit Margin | -142.74 |
| EBITDA Margin | -127.86 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.60 |
| FCF Yield | -1.91 |
Stock Splits
iNtRON Biotechnology, Inc.'s most recent stock split took place on January 10, 2019 with a 1:2 split ratio.
| Last Split Date | 1/10/2019 |
| Split Ratio | 1:2 |
Scores
iNtRON Biotechnology, Inc. posts an Altman Z-Score of 13.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.15 |